In its opening submissions in a trade mark case brought by Botox maker Allergan, Australian cosmetics brand Self Care compared its used of the word Botox to describe its alternative cosmetic products to the iPhone secondary accessories market, saying its use did not imply an affiliation with the injectable wrinkle treatment’s maker.
Maurice Blackburn’s shareholder class action against AMP — the only action not backed by a litigation funder — has been picked as the winner in a fierce battle of law firms vying to lead a high stakes case over the wealth manager’s fees for no service scandal.
A ruling by a judge deciding a four-way contest to run a shareholder class action against AMP is expected this week, a judgment significant not just because it is the first time a court in Australia has been asked to choose among so many competing representative cases.
Telecom giant Optus has been hit with a $25,000 criminal fine after pleading guilty to four charges of failing to disclose political donations in its development applications.
The Chief Justice of the Federal Court wants four referees to weigh what’s expected to be voluminous expert evidence in three class actions against the Commonwealth of Australia over exposure to allegedly toxic foam used on a government military bases, saying with 60 class actions pending in the Federal Court, devoting a single judge to the case for months on end should be a “mechanism of last resort”.
An eight-day joint hearing in cases brought by Allergan alleging infringement of its Botox trade mark, which was due to commence Monday, has been unexpectedly vacated by the court, with barristers and legal teams left in the dark about the reasons.
An appeals court has overturned a ruling awarding $2 million in compensation to United Petroleum after the state government compulsorily acquired land on which the petrol retailer operated a service station and restaurant.
Unilever is not ready to put its long-running consumer case against competitor Beiersdorf to rest, filing a challenge to a ruling that Beiersdorf did not make misleading claims about its Nivea clinical strength deodorant products.
Pharmaceutical giant Allergan has streamlined its trade mark case against Self Care Corporation, which makes products marketed as Botox alternatives.
The investor behind a failed class action against the Public Trustee of Queensland over the collapse of Octaviar Group has escaped a bid by the Trustee for maximum costs, with a judge ruling the case was not a “nakedly speculative venture” by the funder.